EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Outcomes of Haploidentical Stem Cell Transplantation in Upfront and Salvage Settings for Adult Patients with Severe Aplastic Anemia

Jihyuk Lee, Sung-Eun Lee, Daehun Kwag, Sung-Soo Park, Silvia Park, Jieun Uhm, Jong Wook Lee

Transplantation and Cellular Therapy · 2025-11 · 31 (11) · 928.e1-928.e12

DOI: 10.1016/j.jtct.2025.08.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation and Cellular Therapy, 2025-11. Verfasst von Jihyuk Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Hanyang University Seoul Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Anemia, Aplastic, Salvage Therapy, Transplantation, Haploidentical, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thanks to advances in controlling graft failure and graft-versus-host disease (GVHD), haploidentical stem cell transplantation from a related mismatched donor (Haplo-SCT) is possible in adult patients with severe aplastic anemia (SAA). However, because of concerns about morbidity and mortality, Haplo-SCT has been used as salvage treatment after the failure of immunosuppressive therapy. In this study, we aimed to evaluate the feasibility of Haplo-SCT for adult patients with SAA in both the upfront and salvage settings. We analyzed 68 consecutive patients who underwent Haplo-SCT between October 2014 and January 2023. Thirty-six (52.9%) patients received salvage Haplo-SCT, and 32 (47.1%) patients underwent upfront Haplo-SCT. All patients received a conditioning regimen of 600 cGy fractionated TBI (200 cGy, 3 times) and fludarabine (30 mg/m2/day) for 5 days. GVHD prophylaxis consisted of antithymocyte globulin (2.5 mg/kg/day for 2 days), tacrolimus, and methotrexate. All patients received peripheral blood as a stem cell source. Outcomes between upfront and salvage Haplo-SCT groups were compared with Log-rank test or Gray's test. Cox proportional hazard model was used to assess factors affecting the GVHD-free failure-free survival (GFFS). The mean age was 37.1 ± 13.0 yr, and 30 (44.1%) patients had very SAA at transplantation. The haploidentical donors were parents (n = 18), siblings (n = 30), offspring (n = 17), and others (n = 3). All patients achieved primary engraftment. The cumulative incidence of acute GVHD (grade ≥II) and chronic GVHD (≥moderate) was 26.5% at 100 days and 9.3% at 4 yr, respectively, and it did not differ between upfront and salvage Haplo-SCT (31.2% versus 22.2%; P = .50, 13.0% versus 5.9%; P = .266). During a median follow-up of 54 mo, the 4-yr overall survival (OS) and failure-free survival were 93.9% and 92.4%, respectively. Four-year OS after upfront and salvage Haplo-SCT was 93.8% and 94.2%, respectively (P = .874). Four-year GFFS was 78.9%, and it did not differ significantly between upfront and salvage Haplo-SCT (71.3% versus 85.8%, P = .143). Furthermore, after adjusting for potential factors affecting GFFS (patient age and comorbidity index), no difference in GFFS was shown between upfront and salvage Haplo-SCT. Our results suggest that Haplo-SCT can be an effective option in both upfront and salvage settings when fully matched donors are not available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, AplasticSalvage TherapyTransplantation, HaploidenticalHematopoietic Stem Cell TransplantationHumansAdultFemaleMaleMiddle AgedGraft vs Host DiseaseTransplantation ConditioningTreatment OutcomeYoung AdultAdolescentRetrospective Studies

Stichwörter der Autor:innen

Conditioning regimenEngraftment failureGraft-versus-host diseaseHaploidentical stem cell transplantationImmunosuppressive therapySevere aplastic anemia

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Hanyang University Seoul Hospital, Seoul, Republic of Korea.
  • Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Hematology-Oncology, Hanyang University Seoul Hospital, Seoul, Republic of Korea. Electronic address: jwlee@hyumc.com.

Zitieren

APA

Lee, J., Lee, S. E., Kwag, D., Park, S. S., Park, S., Uhm, J., & Lee, J. W. (2025). Outcomes of Haploidentical Stem Cell Transplantation in Upfront and Salvage Settings for Adult Patients with Severe Aplastic Anemia. Transplantation and Cellular Therapy, 31(11), 928.e1-928.e12. https://doi.org/10.1016/j.jtct.2025.08.005

Vancouver

Lee J, Lee SE, Kwag D, Park SS, Park S, Uhm J, et al. Outcomes of Haploidentical Stem Cell Transplantation in Upfront and Salvage Settings for Adult Patients with Severe Aplastic Anemia. Transplantation and Cellular Therapy. 2025;31(11):928.e1-928.e12. doi:10.1016/j.jtct.2025.08.005

BibTeX
@article{Lee2025,
  author = {Lee, Jihyuk and Lee, Sung-Eun and Kwag, Daehun and Park, Sung-Soo and Park, Silvia and Uhm, Jieun and Lee, Jong Wook},
  title = {Outcomes of Haploidentical Stem Cell Transplantation in Upfront and Salvage Settings for Adult Patients with Severe Aplastic Anemia},
  journal = {Transplantation and Cellular Therapy},
  year = {2025},
  volume = {31},
  number = {11},
  pages = {928.e1--928.e12},
  doi = {10.1016/j.jtct.2025.08.005}
}
Kostenlos starten →